Tachycardia Management

Management

Control Strategy for Atrial Fibrillation

Lenient heart rate (HR) control, compared to strict HR control, may be beneficial in patients with persistent atrial fibrillation who have stable ventricular function (LVEF >0.40) and/or no symptoms related to atrial fibrillation
- Lenient HR control is defined as achieving resting HR <110 beats per minute (bpm); strict HR control is <80 bpm at rest and HR <110 bpm during a 6-minute walk
- May be considered as the initial HR target for rate control therapy
- Left ventricular function should be monitored in these patients
One trial revealed that in patients with atrial fibrillation and systolic heart failure, routine strategy of rhythm control is not beneficial compared to rate control strategy

Empagliflozin near to us: Insights from its use in Asians

09 Jul 2020

In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure

21 Mar 2023

Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.

Empagliflozin’s clinical endorsement: Revolutionising guidelines across specialties

08 Jun 2020

In this third issue we take a look at how empagliflozin made a bold impact on clinical guidelines across multiple specialties. We will explore how existing treatment recommendations were altered, and summarise the current guidelines and future perspectives of empagliflozin’s use.